Skip to main content

Aclara Posts Uptick in Q2 Revenues as Losses Decrease; Acquisition By Virologic Still On

NEW YORK, Aug. 6 (GenomeWeb News) - Aclara Biosciences on Wednesday reported an uptick in second-quarter revenue amid significantly decreased R&D spending and a narrowed net loss.

 

The company, which is slated to be acquired by ViroLogic during the fourth quarter, generated $515,000 in receipts for the three months ended June 30 compared with $405,000 in the year-ago quarter.

 

Second-quarter R&D spending shrank to $2.7 million from $4 million year over year.

 

Largely as a result, net loss decreased to $4.9 million, or $.13 per share, from $5.1 million, or $.14 per share, during the second quarter last year.

 

Aclara, based in Mountain View, Calif., said it had around $81.9 million in cash, equivalents, and marketable securities as of June 30.

 

Click here for more information.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.